PHILADELPHIA (AP) _ Spark Therapeutics Inc. (ONCE) on Tuesday reported a loss of $65 million in its third quarter.
On a per-share basis, the Philadelphia-based company said it had a loss of $1.90.
The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.80 per share.
The gene therapy developer posted revenue of $1.9 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $1.4 million.
Spark Therapeutics shares have increased 64 percent since the beginning of the year. The stock has climbed 86 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ONCE at https://www.zacks.com/ap/ONCE